Phase III study of palonosetron for prevention of chemotherapy-induced nausea and vomiting in pediatric patients
ConclusionWe demonstrated the efficacy of palonosetron in pediatric patients receiving highly emetogenic chemotherapy or moderately emetogenic chemotherapy and confirmed the appropriateness of the 20 μg/kg dose, regardless of age, considering the safety and pharmacokinetic profiles.Trial registrationJapicCTI-163305, registered 6 June 2016.
Source: Japanese Journal of Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer & Oncology | Chemotherapy | Dexamethasone | Japan Health | Pediatrics | Study | USA Health | Zofran